Quick Answer
CITIUS ONCOLOGY, INC. reported Net Income Loss of -$24.76 million for the year ending 2025.
- CITIUS ONCOLOGY, INC. showed a decrease of -17.1% in Net Income Loss from 2024 to 2025.
- This data is from CITIUS ONCOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on December 23, 2025.
- XBRL data for this metric is available from 2022 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$9.4 thousand | Q2 2021: -$724.00 | Q1 2023: $611.7 thousand | Q2 2023: $616.3 thousand | Q3 2023: $157.9 thousand | Q4 2023: -$4.73 million | Q1 2024: -$4.84 million | Q2 2024: -$4.77 million | Q4 2024: -$6.66 million | Q1 2025: -$7.74 million | Q2 2025: -$5.37 million | Q4 2025: -$5.53 million.
- Over the full 5 years of available data (2022 to 2025), CITIUS ONCOLOGY, INC.'s Net Income Loss has declined by 6,602.3%.
- Historical annual values: Fiscal year 2025: -$24.76 million | Fiscal year 2024: -$21.15 million | Fiscal year 2023: $2.42 million | Fiscal year 2023: -$12.70 million | Fiscal year 2022: $380.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: